Log in
Forgot password ?
Become a member for free
Sign up
Dynamic quotes

school135perm Homepage > Equities > Nasdaq > Retrophin Inc RTRX

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Retrophin : Ex-lawyer for pharma executive Shkreli convicted of aiding fraud scheme

12/28/2017 | 03:18am CET
FILE PHOTO: Former drug company executive Martin Shkreli exits U.S. District Court after being convicted of securities fraud, in the Brooklyn borough of New York City

A New York lawyer who once advised Martin Shkreli was convicted on Wednesday of helping him defraud a pharmaceutical company, a charge a different jury cleared the drug executive of when it found him guilty of securities fraud earlier this year.

Evan Greebel, who was outside counsel to Shkreli's former company Retrophin Inc, was found guilty by a federal jury in Brooklyn of charges he conspired to commit wire fraud and securities fraud, prosecutors said.

"We are shocked by the verdict," said Reed Brodsky, a lawyer for Greebel. "We will continue to fight for justice for Evan Greebel and his family."

Acting U.S. Attorney Bridget Rohde in Brooklyn said the verdict sent a message to lawyers that they will be held accountable when they "use their legal expertise to facilitate the commission of crime."

The verdict came after a different jury in August found Shkreli guilty of defrauding hedge fund investors, but not guilty of conspiring with Greebel to steal from Retrophin. He has denied wrongdoing.

Greebel, 44, was a partner at the law firm Katten Muchin Rosenman when he was working for Retrophin. He later joined the firm Kaye Scholer, but resigned after his arrest in December 2015.

Shkreli, 34, became notorious in 2015 when he raised the price of anti-parasitic drug Daraprim to $750 a pill, from $13.50, as chief executive of Turing Pharmaceuticals. The price hike is unrelated to the criminal case.

The charges he and Greebel faced related to Shkreli's management of his previous drug company, Retrophin, and of two hedge funds, MSMB Capital and MSMB Healthcare, from 2009 to 2014.

Prosecutors have said that Shkreli lied about the funds' finances to lure investors and concealed devastating trading losses. They said he paid investors back with money and shares stolen from Retrophin, which he founded in 2011.

Prosecutors said Greebel assisted Shkreli in defrauding Retrophin through a series of settlement and sham consulting agreements.

In September, following his conviction, Shkreli was jailed after he offered a $5,000 reward in a posting on Facebook for a strand of former presidential candidate Hillary Clinton's hair. That prompted U.S. District Judge Kiyo Matsumoto to revoke his bail.

Greebel denied wrongdoing, and at trial, his lawyers sought to distance their client from Shkreli, whose provocative public behavior earned him the nickname "pharma bro."

Brodsky told jurors during his opening statement that Shkreli lied to Greebel just as he lied to investors.

Greebel was also accused of conspiring with Shkreli to exercise secret control over Retrophin shares belonging to several other shareholders. Shkreli was found guilty of that charge during his trial.

(Reporting by Jan Wolfe and Nate Raymond; Editing by Frances Kerry and Tom Brown)

By Jan Wolfe and Nate Raymond

Latest news on RETROPHIN INC
01/11RETROPHIN : Gift to Establish Rare Disease Network at Children's National
01/10RETROPHIN : Gift to Establish Rare Disease Network at Children`s National
01/09RETROPHIN : Gift to Establish Rare Disease Network at Children's National
01/09RETROPHIN : Provides Corporate Update and 2018 Outlook
01/08RETROPHIN : and Censa Pharmaceuticals Enter into Strategic Collaboration to Adva..
01/08RETROPHIN, INC. : Results of Operations and Financial Condition, Financial State..
01/08Retrophin Provides Corporate Update and 2018 Outlook
01/05RETROPHIN, INC. (NASDAQ : RTRX) Files An 8-K Other Events
01/05RETROPHIN, INC. : Other Events (form 8-K)
01/05Retrophin and Censa Pharmaceuticals Enter into Strategic Collaboration to Adv..
More news
News from SeekingAlpha
01/12Retrophin (RTRX) Presents At 36th Annual J.P. Morgan Healthcare Conference - ..
01/10YOUR DAILY PHARMA SCOOP : Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides..
01/06YOUR DAILY PHARMA SCOOP : Lipocine Ahead Of Ad Com, Ohr's MAKO Study Fails, Zafg..
01/05Retrophin teams up with Censa Pharma to develop PKU candidate
2017WALL STREET BREAKFAST : Dow Makes Fresh Attempt At Milestone
Financials ($)
Sales 2017 154 M
EBIT 2017 -46,8 M
Net income 2017 -46,6 M
Finance 2017 253 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 4,50x
EV / Sales 2018 4,24x
Capitalization 948 M
Duration : Period :
Retrophin Inc Technical Analysis Chart | RTRX | US7612991064 | school135perm
Technical analysis trends RETROPHIN INC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 4
Average target price 35,7 $
Spread / Average Target 44%
EPS Revisions
Stephen J. Aselage President, Chief Executive Officer & Director
Gary A. Lyons Independent Chairman
Neil McFarlane Chief Operating Officer
Laura M. Clague Chief Financial Officer & Senior Vice President
William E. Rote Senior VP, Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES10.36%103 247
GENMAB11.27%11 475
EXELIXIS, INC.-0.07%8 899
Copyright © 2018 Surperformance. All rights reserved.